GSK Faces Scrutiny Over Misleading Omjjara Prescription Information
On April 15, 2025, the Prescription Medicines Code of Practice Authority (PMCPA) determined that GlaxoSmithKline (GSK) breached ethical and regulatory standards concerning its drug Omjjara. The PMCPA found that the prescribing information for Omjjara was misleading, particularly for women using hormonal contraceptives, by failing to adequately communicate the need for additional pregnancy prevention measures.
Omjjara is prescribed for adults with myelofibrosis, a rare bone marrow cancer, and for those suffering from moderate to severe anemia. The PMCPA’s findings highlight concerns about the accuracy of information provided to patients and healthcare professionals.
In response, a GSK spokesperson stated, “We take adherence to industry codes and regulations very seriously.” This incident adds to GSK’s history of regulatory challenges, including a $3 billion settlement in 2012 over allegations of illegal marketing practices and failure to report safety data.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-15
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF Technology with CFRP Lands in Nanjing: High-Performance Dispersant Production Line Officially Commissioned
-
Haldia Petrochemicals Pipeline Fire in India Adds Uncertainty to Asia's Naphtha Market
-
Sinochem International Acquires Nantong Xingchen for 2.11 Billion Yuan, Rike Chemical Plans Genyuan New Materials Acquisition – The Changing Landscape of Chemical M&A
-
BASF and IFF Collaborate to Accelerate Innovation in Enzymes and Polymers
-
BASF’s Zhanjiang Integrated Site Commissions New Neopentyl Glycol (NPG) Unit
-
LBB Specialties to Distribute Imerys' Mineral Ingredients in North America
-
When Light Falls on Metal: The Industrial Romance of Xiaomi × BASF
-
Brenntag Expands Distribution of Givaudan’s Active Beauty Ingredients to Malaysia and Singapore
-
When the Chemical Industry Is No Longer Highly Profitable: Sinochem International’s 2.4 Billion Yuan Loss Reveals the Truth About Industry Cycles
-
Sherwin-Williams Completes Acquisition of BASF's Decorative Paints Business in Brazil for $1.15 Billion
Recommend Reading
-
McKinsey Pays to Close a Purdue Liability Chapter
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Roche Keeps German Diagnostics Investment
-
Firm Costs and Weak Demand Lead to High-Level Fluctuations in the Chinese PTA Market
-
Expected Short-term Peak Season Surge, This Week's Polyester Chip Market in China Shows High-level Fluctuations
-
This Week's Styrene Market Fluctuates and Declines (3.30-4.3)
-
BDO market trend continues to rise in China
-
Ethanol Market Prices at High Levels with Consolidation